New drug combo aims to supercharge weight loss in obesity trial
NCT ID NCT06643728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 study tests two drugs, bimagrumab and tirzepatide, alone or together, to see if they help adults with obesity or overweight lose weight safely. About 252 participants without type 2 diabetes will take the drugs or a placebo for up to 70 weeks. The main goal is to measure how much body weight and fat they lose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bimagrumab and tirzepatide (drugs)
What this could lead to
If successful, this could lead to a new combination treatment that helps people with obesity lose more weight and body fat than current options.
What could go wrong
This is an early phase 2 trial with only 252 participants, so results may not apply to everyone. The drugs may cause side effects or not work better than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altus Research
Lake Worth, Florida, 33461, United States
-
Central Research Associates
Birmingham, Alabama, 35205, United States
-
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Jacksonville, Florida, 32256, United States
-
Diablo Clinical Research, Inc.
Walnut Creek, California, 94598, United States
-
East-West Medical Research Institute
Honolulu, Hawaii, 96814, United States
-
Eastside Research Associates
Redmond, Washington, 98052, United States
-
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, 60640, United States
-
Keystone Clinical Studies
Plymouth Meeting, Pennsylvania, 19462, United States
-
Pinnacle Research Group, LLC
Anniston, Alabama, 36207, United States
-
Rainier Clinical Research Center
Renton, Washington, 98057, United States
-
SKY Integrative Medical Center/SKYCRNG
Ridgeland, Mississippi, 39157, United States
-
Suncoast Research Group
Miami, Florida, 33135, United States